Please login to the form below

Not currently logged in
Email:
Password:

Merck acquires experimental MS drug

The worldwide exclusive rights to PI-2301, an experimental multiple sclerosis drug, have been acquired by Merck

The worldwide exclusive development and commercialisation rights to PI-2301, an experimental drug for multiple sclerosis (MS), have been acquired by Merck (known as EMD Chemicals in the US and Canada).

PI-2301 was originally developed by Peptimmune Inc, and is a second-generation peptide copolymer, which is thought to enhance the regulatory response of the immune system. The drug is now ready to enter phase II clinical trials for the treatment of MS and possibly other autoimmune diseases.

MS is an inflammatory condition of the central nervous system. In young adults, it is the  most common, non-traumatic, disabling neurological disease, and it is estimated that around two million people have MS worldwide. The most common symptoms include blurred vision, numbness or tingling in the limbs and problems with strength and coordination, however these symptoms can vary.

Susan Herbert, head of Global Portfolio Development at Merck commented: "We are pleased to strengthen our development pipeline with the PI-2301 compound, which could play a valuable role in the treatment of this debilitating disease."

20th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics